Necroptosis has been identified in multiple progressive neurologic diseases affecting millions of individuals.  Tactile Therapeutics is building a unique pipeline of small molecule degraders that specifically target proteins that drive necroptosis. 

Increasingly, therapeutic development has targeted neuroinflammation as a means to slow degenerative disease progression, but necroptosis remains an underexplored pathway.

Blocking necroptosis offers a unique approach that is mechanistically consistent with slowing disease progression. It may offer a path to measurable clinical benefit.